Dana-Farber Cancer Institute

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Dana-Farber Cancer Institute

https://www.dana-farber.org/

2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business

Playback speed

10 seconds

Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK4/6 Inhibition Is the SoC in the 1st and 2nd-Line Setting

By Dana-Farber Cancer Institute FEATURING Erica Mayer

1,470 views

February 10, 2020

0 Comments

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Breast

21:20

Dana-Farber Cancer Institute

Older Adults With Breast Cancer: Research Updates

Feat. R. Freedman

14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino

22:34

Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney

17:35

Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino

17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino

12:50

Oncology Data Advisor

Expert Perspectives in the Management of TNBC

Feat. S. Tolaney

09:32

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney

04:28

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney

12:48

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Association of Tumor-Infiltrating Lymphoc…

Feat. M. Tesch

11:01

Dana-Farber Cancer Institute

Updates on the Personalized Management of HER2+ eBC for 2023

Feat. A. Waks

14:11

ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…

Feat. P. Tarantino

31:07

Dana-Farber Cancer Institute

Supporting Older Adult Cancer Survivors With a Focus on Breast Cancer

Feat. R. Freedman

39:42

Dana-Farber Cancer Institute

Probing Genome Maintenance Mechanism Through the Lens of BRCA1/2 Syn…

Feat. D. Durocher

33:37

Dana-Farber Cancer Institute

PARPi in Ovarian Cancer: Maximizing Risk/Benefit Ratio

Feat. E. Swisher

33:35

Dana-Farber Cancer Institute

Advances in the Systemic Treatment of BRCA1/2 and PALB2-Associated B…

Feat. F. Lynce

38:50

Dana-Farber Cancer Institute

New Vulnerabilities in BRCAm Cancers

Feat. R. Greenberg

29:11

Dana-Farber Cancer Institute

Redefining BRCAness and Chemotherapy Response

Feat. S. Cantor

36:28

Dana-Farber Cancer Institute

Complexities of Utilizing Immunotherapy in BRCA-Associated Cancers

Feat. J. Guerriero

34:05

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute 2022 SABCS Updates on mBC

Feat. H. Burstein

13:32

Dana-Farber Cancer Institute

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Im…

Feat. P. Tarantino

06:04

Dana-Farber Cancer Institute

Updated Exploratory Analysis of the HER2CLIMB Trial for HER2+ mBC Wi…

Feat. N. Lin

06:53

ecancer

SABCS 2022 Primary Results From the POSITIVE Trial: Interruption of …

Feat. A. Partridge

05:45

SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney

02:31

SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rat…

Feat. S. Tolaney

16:49

SABCS 2022 Conference Coverage

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

Feat. F. Lynce

14:58

SABCS 2022 Conference Coverage

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

Feat. J. Pablo Leone

14:31

Dana-Farber Cancer Institute

An Overview of Male Breast Cancer

Feat. J. Pablo Leone

07:56

Dana-Farber Cancer Institute

Aiming at a Tailored Cure for ERBB2+ Metastatic Breast Cancer

Feat. P. Tarantino

04:19

Dana-Farber Cancer Institute

ESMO 2021 Update on T-DXd +/- Pertuzumab vs. THP in 1L HER2+ MBC: DE…

Feat. S. Tolaney

11:30

i3 Health

Optimizing Treatment of MBC: Predictive / Prognostic Biomarkers, Ove…

Feat. S. Tolaney, I. Bleiweiss, M. Ross

07:55

Dana-Farber Cancer Institute

2021 ASCO Updates From eMonarcHER on HR+, HER2+, N+, High-Risk eBC: …

Feat. S. Tolaney

09:08

Dana-Farber Cancer Institute

Results from monarcHER Trial on CDK4/6 Inhibitors + ET: Can Abemacic…

Feat. S. Tolaney

25:16

Dana-Farber Cancer Institute

Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK…

Feat. E. Mayer

07:38

Dana-Farber Cancer Institute

2019 APHINITY Trial Update: Fewer Deaths Seen in Addition of Pertuzu…

Feat. S. Tolaney

07:23

Dana-Farber Cancer Institute

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Feat. S. Tolaney

07:40

Dana-Farber Cancer Institute

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…

Feat. S. Tolaney

07:43

Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel